Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome
Journal of Clinical Oncology - United States
doi 10.1200/jco.1999.17.2.600
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 1999
Authors
Publisher
American Society of Clinical Oncology (ASCO)